ALDX Investor News: Losses Reported for Aldeyra Therapeutics

Shareholders may have claims against the company following stock declines.

Mar. 29, 2026 at 4:38am

Got story updates? Submit your updates here. ›

A law firm is investigating potential claims against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who have suffered losses related to the company's stock. The investigation is focused on determining if the company made misleading statements or failed to disclose material information that impacted the stock price.

Why it matters

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for immune-mediated diseases. The potential for legal claims against the company could impact investor confidence and the future of the business.

The details

The investigation by the law firm is examining whether Aldeyra Therapeutics issued false or misleading statements, or failed to disclose material information, regarding the company's business, operations, and prospects. This could have artificially inflated the company's stock price, leading to losses for investors when the true state of the company's affairs was revealed.

  • The investigation was launched on March 28, 2026.

The players

Aldeyra Therapeutics, Inc.

A clinical-stage biotechnology company focused on the development of novel therapies for immune-mediated diseases.

Got photos? Submit your photos here. ›

What’s next

The law firm is encouraging any investors who have suffered losses to contact them to discuss their potential legal options.

The takeaway

This investigation highlights the importance of transparency and accurate disclosure for publicly traded companies, as investors rely on this information to make informed decisions about their investments.